Dr Jo Hegarty
MB Bch BAO, MRCPCH (UK), PG Dip AeroRT (Otago)
Research | Current
hypoglycaemia Prevention with Oral Dextrose in newborn babies
Hypoglycaemia is the commonest metabolic disorder of the newborn, and the only known common preventable cause of brain damage in newborn babies. Neonatal hypoglycaemia treatment commonly requires admission to the newborn intensive care unit (NICU), separating mothers and babies and interfering with the establishment of breast-feeding, thus incurring high social and financial cost.
hPOD is a multi-centre, double-blinded, randomised, placebo-controlled trial, comparing 40% dextrose gel with an identically appearing placebo gel. Babies who are at risk of hypoglycaemia (infants of diabetic mothers, preterm, small- or large-for-gestational age, other e.g. maternal medication) and unlikely to require NICU admission for other reasons are randomised to receive 40% dextrose gel or identically appearing placebo gel. The primary outcome is admission to NICU; secondary outcomes include incidence of hypoglycaemia, breastfeeding rates, costs of care before discharge and assessment of neurodevelopmental outcome at 2 years of age.
For more information see: http://www.liggins.auckland.ac.nz/uoa/hpod-study
Areas of expertise
Selected publications and creative works (Research Outputs)
- Hegarty, J. E., Harding, J. E., Gamble, G. D., Crowther, C. A., Edlin, R., & Alsweiler, J. M. (2016). Prophylactic oral dextrose gel for newborn babies at risk of neonatal hypoglycaemia: A randomised controlled dose-finding trial (the pre-hPOD study). PLoS Medicine, 13 (10)10.1371/journal.pmed.1002155
Other University of Auckland co-authors: Caroline Crowther, Jane Harding, Jane Alsweiler, Richard Edlin, Greg Gamble